Organon stock had its Relative Strength (RS) Rating upgraded from 78 to 83 Tuesday.
This exclusive rating from Investor's Business Daily identifies price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the market's biggest winners often have an 80 or higher RS Rating in the early stages of their moves.
Risk Management In The Stock Market: How Much Money To Invest Now
Is Organon Stock A Buy?
Organon stock broke out earlier, but is now trading approximately 4% below the prior 21.98 entry from a flat base. If a stock you're watching breaks past a buy point then retreats 7% or more below the original entry price, it's considered a failed base. It's best to wait for the stock to form a new base and breakout. Also keep in mind that the most recent consolidation is a later-stage base, and those involve more risk.
The generic drug firm reported -15% earnings growth in its most recent report. Revenue rose 0%.
Organon stock holds the No. 10 rank among its peers in the Medical-Generic Drugs industry group. Collegium Pharmaceutical, Dr. Reddy's Labs ADR and Teva Pharmaceutical ADR are among the top 5 highly rated stocks within the group.
